Is Corcept Therapeutics Incorporated (CORT) overvalued? · P/E 199, rev $675.0M
Corcept Therapeutics Incorporated (CORT) is a biotechnology company listed on US.
This page asks whether Corcept Therapeutics Incorporated (CORT) looks expensive on cached numbers — not a short thesis.
Latest reported CORT revenue for 2024-12-31 was $675.0M. Net income was $141.2M. Revenue was up 39.9% from 2023-12-31 to 2024-12-31. CORT currently screens at market cap $7.46B and trailing P/E 198.5.
CORT currently screens at market cap $7.46B and trailing P/E 198.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CORT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CORT stock page for the full model, not this heading.
Not investment advice.